Eisai Inc.’s U.S. headquarters at 200 Metro Blvd. in Nutley. — Courtesy: SJP
By Joshua Burd
SJP Project Solutions has completed its buildout of Eisai Inc.’s new headquarters in Nutley, where the pharmaceutical company occupies 300,000 square feet as part of the ON3 campus.
In a news release, the construction team said the property at 200 Metro Blvd. is home to some 1,200 corporate and research and development workers that transferred to the space earlier this year, following a lease signed in August 2020 between Eisai and Prism Capital Partners. The oncology- and neurology-focused drugmaker subsequently tapped SJP Project Solutions, the third-party building and project management arm of SJP Properties, to spearhead the delivery of what it has described as a new hybrid, technologically advanced work setting.
SJP worked in conjunction with Eisai’s in-house team to complete the project while working with Prism, ON3’s owner and master developer, on the base-building improvements. It also collaborated with leading global architecture firms HLW and AMA on the design and build-out of the space.
“New Jersey has a long history of serving as an incubator for some of the most innovative companies in the pharmaceutical and life science spaces and Eisai’s new headquarters at ON3 will set the standard for the future of the industry’s workplaces,” said Andrew Natale, chief operating officer at SJP Project Solutions. “We are proud to have helped deliver a best-in-class headquarters that will support Eisai’s peerless standard of research and development, as well as its relentless focus on promoting teamwork, safety and innovation in the office.”
Eisai Inc., the U.S. subsidiary of Japan-based Eisai Co. Ltd., relocated from Woodcliff Lake, taking the entirety of 200 Metro Blvd. at ON3. The company’s focus includes treatments for cancer, Alzheimer’s disease and other neurodegenerative diseases.